Los Angeles Capital Management LLC Has $340,000 Holdings in Cerus Co. (NASDAQ:CERS)

Los Angeles Capital Management LLC raised its position in Cerus Co. (NASDAQ:CERS) by 153.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 195,224 shares of the biotechnology company’s stock after buying an additional 118,280 shares during the period. Los Angeles Capital Management LLC owned 0.11% of Cerus worth $340,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CERS. The Manufacturers Life Insurance Company lifted its position in shares of Cerus by 10.9% during the second quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 7,209 shares in the last quarter. Creative Planning lifted its position in shares of Cerus by 51.3% during the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,411 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Cerus by 4.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 8,982 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of Cerus by 38.4% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 9,737 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Cerus by 4.4% during the second quarter. Rhumbline Advisers now owns 252,444 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 10,739 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cerus

In other Cerus news, CFO Kevin Dennis Green sold 28,385 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. This represents a 4.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.40% of the stock is currently owned by company insiders.

Cerus Trading Down 4.4 %

Shares of NASDAQ CERS opened at $1.72 on Monday. The company’s 50 day simple moving average is $1.78 and its 200 day simple moving average is $1.92. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.59. The firm has a market capitalization of $319.42 million, a P/E ratio of -15.64 and a beta of 1.20. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus reduced their target price on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.